AbbVie’s 2025 global regulatory approvals, licensing collaborations, M&A activities, clinical developments, and financial performance disclosures — a consolidated summary

AbbVie’s 2025 product regulatory approval progress, as disclosed on its official website, is summarized in the table below. Highlights include: Emblaveo approved in the U.S. for bacterial infections; Mavyret approved in the U.S. for chronic hepatitis C in children aged three years and older; Rinvoq approved in both the EU and the U.S. for adult giant cell arteritis, and submitted for ulcerative colitis and Crohn’s disease in the U.S.; aesthetic product TrenibotE submitted in the U.S. for moderate-to-severe crow’s feet; Skinvive submitted in the U.S. for neck wrinkles; Emrelis approved in the U.S. for non-small cell lung cancer; Venclexta plus acalabrutinib submitted in the U.S. for chronic lymphocytic leukemia; Pivekimab sunirine submitted in the U.S. for plasmacytoid dendritic cell neoplasm; Epkinly combined with rituximab approved in the U.S. for follicular lymphoma; and tavapadon submitted in the U.S. for Parkinson’s disease. Licensing and collaboration activities in 2025 include: — A collaboration with Simcere Pharmaceutical’s subsidiary Simcere Zaiming on SIM0500 for multiple myeloma; — A partnership with IGI Therapeutics SA on ISB2001 for multiple myeloma; — A collaboration with Neomorph on molecular glue degraders for oncology and immunology indications; — A partnership with Xilio Therapeutics on masked cell engagers for tumor immunotherapy; — A collaboration with Gubra on GUB014295 for obesity; — A partnership with ADARx Pharmaceuticals on small interfering RNA (siRNA) therapeutics across multiple disease areas.

A free-ranging discussion sparked by the 2025 R&D investment figures of multinational pharmaceutical companies

Today, Insight’s WeChat Official Account published an article summarizing the R&D investments of top pharmaceutical companies in 2025, listing the top 10 spenders. Notably, the tenth-ranked company invested USD 9.096 billion — meaning that exceeding USD 9 billion was the threshold to enter the top 10. Among these, Merck & Co. (MSD) allocated the highest proportion of revenue to R&D (24.3%), while AbbVie allocated the lowest (14.9%). More intriguing is the year-on-year change in R&D spending: only three companies posted positive growth — AstraZeneca (+4%), Eli Lilly (+21%), and GSK (+19%). Frankly, this surprised me — yet also felt oddly inevitable. The surprise stems from the perennial ‘patent cliff’ narrative: the persistent need to fill anticipated sales gaps left by expiring patents has long been a familiar refrain. So, logically, it seems puzzling that seven companies reported declining R&D investment. Yet the inevitability lies in the impact of the U.S.-style ‘drug price negotiation’ policy: although analyses often suggest much of the profit reduction is absorbed by distribution channels (analogous to how part of the margin erosion following China’s centralized procurement is reportedly absorbed by intermediaries), no one would credibly claim such policies have zero effect on sales forecasts or product lifecycle planning. Thus, cost optimization and efficiency enhancement become critical. R&D represents a major cost component — streamlining pipelines, deprioritizing or halting high-risk, non-core programs can theoretically reduce costs. Simultaneously, improving R&D productivity — for instance, by partnering with more efficient external service providers — becomes essential (this evokes the 2025 BD boom and the recovery in financial performance among leading CRDMO firms, including the WuXi AppTec ecosystem). In summary: industry-wide profit volatility driven by pivotal market-level policy shifts demands compensatory strategies. Concurrent pressures from cost discipline and patent cliffs compel companies to seek more effective models for organizing and deploying R&D resources. In this context, becoming the high-value-for-money partner may well be where opportunity — and momentum — emerges.

AbbVie expands Oxford R&D facility as part of £120 million-plus investment

2 days ago

AbbVie announced a £120 million investment to expand its Oxford R&D facility, enhancing capabilities in immunology, neuroscience, and oncology. The expansion supports new disease target research and strengthens collaborations with UK academic institutions.

reuters

2026-04-29

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

2026-06-30

US House committee opens investigation into Merck, AbbVie China drug trials

2026-11-03

AbbVie expands Oxford R&D facility as part of £120 million-plus investment

AbbVie expands Oxford R&D facility as part of £120 million-plus investment

FAQ